Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome

Completed · Phase 2 · Has a placebo group

Conditions studied: Acute Coronary Syndrome

In brief

This is a multi-center, randomized, double-blind, placebo-controlled study to determine the safety and tolerability of E5555 in subjects with Acute coronary syndrome (ACS).

Key facts

Study ID
NCT00548587
Run by
Eisai Inc.
People needed
600
Starts
2007-10-01
Expected to finish
2009-08-01
Last updated by the study team
2016-02-04

Who can join

Age: 45 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.